Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
Proteomics for precision medicine: Next-generation testing to
indicate future cardiovascular risk and improve outcomes
Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of cardiovascular disease (CVD). This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major cardiovascular (CV) event.
Topics covered include:
- The capabilities of proteomics
- How comprehensive protein detection technology can accurately predict major cardiovascular events
- How proteomic testing can ultimately improve outcomes
Nelson Trujillo, MD
Cardiologist
Boulder Heart at Anderson Medical Center
Rosalyn Gill, PhD
Vice President, Medical Affairs
SomaLogic, Inc.
Todd Johnson
Executive Vice President, Diagnostics
Business Unit
SomaLogic, Inc.
Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
A presentation by Nelson Trujillo, MD, Rosalyn Gill, PhD, and Todd Johnson
More webinars
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.
WebinarData Summit 2025
Take your research further with expert insights from the SomaScan™ Data Summit. Explore the latest platform updates, advanced data analysis tools, and innovative applications for SOMAmer™ reagents. From optimizing sample quality to customizing panels beyond 7K and 11K, this event is packed with knowledge to help you get the most from your data.